A low anion gap occurs when serum anion gap values fall below 8 mEq/L, indicating an imbalance in unmeasured anions and cations. Certain medications disrupt electrolyte balance and alter the anion gap, often by increasing unmeasured cations like calcium or magnesium, or decreasing unmeasured anions such as albumin.
The anion gap is calculated as: Na⁺ - (Cl⁻ + HCO₃⁻). A normal range is typically 8-16 mEq/L. Values below 8 suggest either reduced unmeasured anions or elevated unmeasured cations. While most clinical attention focuses on high anion gap acidosis, a low anion gap is less common but equally important to recognize.
Medications that cause a low anion gap do so through mechanisms including hypercalcemia, hypermagnesemia, or hypoalbuminemia. These changes reduce the concentration of unmeasured anions relative to measured ions, lowering the anion gap. This effect is often subtle and easily missed unless clinicians actively consider it during lab interpretation.
The anion gap reflects the difference between measured cations (primarily sodium) and measured anions (chloride and bicarbonate). Unmeasured anions-such as phosphate, sulfate, and proteins like albumin-contribute to the gap. When these unmeasured anions decrease or when unmeasured cations increase, the gap narrows.
For example, severe hypoalbuminemia reduces negatively charged proteins, effectively lowering the anion gap. Similarly, elevated calcium levels (hypercalcemia) increase unmeasured cations, reducing the gap. Some medications induce these shifts pharmacologically rather than through disease processes.
According to UpToDate, a low anion gap is rarely due to primary metabolic disturbances and more often results from laboratory artifacts or medication effects. It's critical to rule out analytical errors-such as lithium interference or sample hemolysis-before attributing a low gap to drugs.
Several medications have documented associations with a low anion gap. These include:
A 2019 study published in Clinical Chemistry reported that patients receiving IVIG at doses above 2 g/kg/day had a median anion gap reduction of 4.2 mEq/L compared to baseline. The effect was reversible upon discontinuation, confirming the drug's role.
| Medication | Primary Mechanism | Typical Dose Range | Anion Gap Reduction |
|---|---|---|---|
| IVIG (intravenous immunoglobulin) | Increased plasma protein concentration | 2-4 g/kg/day | 2-6 mEq/L drop |
| Calcium chloride | Elevated unmeasured cations (Ca²⁺) | 1-2 g IV over 10-30 min | 3-5 mEq/L drop |
| Chloral hydrate | Metabolite-induced osmolar shift | 50-100 mg/kg/day | 1-3 mEq/L drop |
| Amphotericin B | Tubular dysfunction → hypercalcemia & hypermagnesemia | 0.3-0.6 mg/kg/day | 2-4 mEq/L drop |
Not all cases of low anion gap are drug-related. Conditions like multiple myeloma, severe liver disease, or paraproteinemias can also lower the gap. However, medication-induced cases are among the most reversible and preventable.
Many clinicians assume a low anion gap signals a serious illness like renal failure or sepsis. But in reality, it's often a medication side effect. A 2021 review in Journal of Clinical Pathology found that 68% of low anion gap cases in hospitalized patients were attributable to drugs, not underlying disease.
Another frequent error is confusing a low anion gap with pseudohyponatremia. Pseudohyponatremia occurs when high lipids or proteins displace water in blood samples, leading to falsely low sodium readings. This can mimic a low anion gap, but the actual gap remains normal. Always verify sodium levels using direct ion-selective electrode methods when suspecting artifact.
One non-obvious point: low anion gap from medications may coexist with normal or even high serum calcium. This happens because calcium's contribution to unmeasured cations is independent of albumin binding. Thus, a patient with normal albumin but high calcium can still show a low anion gap.
In a case reported by the American Journal of Hematology (2020), a 67-year-old woman with chronic lymphocytic leukemia received IVIG at 2 g/kg/day for immune thrombocytopenia. Her baseline anion gap was 12 mEq/L. After two days of infusion, her gap dropped to 5 mEq/L. Serum calcium rose from 9.2 mg/dL to 10.8 mg/dL, and albumin remained stable.
Renal function was normal. Repeat labs confirmed the change was not due to hemolysis or machine error. Discontinuing IVIG led to normalization of the anion gap within 48 hours. The patient experienced no symptoms related to the change, underscoring that a low anion gap can be asymptomatic and medication-driven.
This case illustrates that monitoring the anion gap during high-dose IVIG therapy is essential. Without awareness, clinicians might misdiagnose metabolic acidosis or investigate unnecessary renal or hepatic causes.
If a low anion gap is detected, evaluate for medication exposure first. Review recent prescriptions, especially IVIG, calcium supplements, or sedatives. Confirm lab accuracy by checking for hemolysis, lipemia, or sample handling issues.
Consider measuring unmeasured anions via serum protein electrophoresis or serum free light chains if monoclonal gammopathy is suspected. Also assess calcium, magnesium, and albumin levels. A corrected anion gap using albumin can help detect subtle changes.
Low anion gap is not a standalone diagnosis. It's a red flag signaling potential drug interaction or metabolic disturbance. Recognizing which medications contribute allows timely intervention and prevents downstream complications.
Some patients with low anion gap develop neurological symptoms, particularly if associated with hypercalcemia. Symptoms like confusion, fatigue, or muscle weakness may appear. In such cases, addressing the underlying cause-often medication-can reverse both the lab abnormality and clinical presentation.
For those experiencing persistent low anion gap despite stopping suspected drugs, further evaluation for rare conditions like hypergammaglobulinemia or congenital disorders of anion transport is warranted. But in most cases, the root cause is pharmacological.
Medications causing a low anion gap are often overlooked because they don't trigger classic acid-base alarms. Yet their impact on electrolyte balance is measurable and clinically relevant. Awareness, lab verification, and medication review are key steps in managing this rare but important phenomenon.